Trial Profile
A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AMG 319 (Primary)
- Indications Head and neck cancer; Human papillomavirus infections; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics
- 16 Jul 2018 Status changed from recruiting to discontinued.
- 05 Jun 2018 Results (n=22) quantifying immunological effects of AMG319 on the tumour microenvironment presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jan 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.